These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37741483)

  • 1. Unveiling clinically significant PPARγ mutations for thiazolidinedione treatment responsiveness through atomistic simulations.
    Shahrear S; Islam ABMMK
    Int J Biol Macromol; 2023 Dec; 253(Pt 4):126990. PubMed ID: 37741483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pharmacogenetic Approach to the Treatment of Patients With
    Agostini M; Schoenmakers E; Beig J; Fairall L; Szatmari I; Rajanayagam O; Muskett FW; Adams C; Marais AD; O'Rahilly S; Semple RK; Nagy L; Majithia AR; Schwabe JWR; Blom DJ; Murphy R; Chatterjee K; Savage DB
    Diabetes; 2018 Jun; 67(6):1086-1092. PubMed ID: 29622583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
    Richard CL; Blay J
    Int J Oncol; 2007 May; 30(5):1215-22. PubMed ID: 17390024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
    Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
    J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
    Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
    J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins.
    Álvarez-Almazán S; Bello M; Tamay-Cach F; Martínez-Archundia M; Alemán-González-Duhart D; Correa-Basurto J; Mendieta-Wejebe JE
    Biochem Pharmacol; 2017 Oct; 142():168-193. PubMed ID: 28716729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
    Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
    Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands.
    Mottin M; Souza PC; Ricci CG; Skaf MS
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
    Lu P; Zhao Z
    Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system.
    Auclair M; Vigouroux C; Boccara F; Capel E; Vigeral C; Guerci B; Lascols O; Capeau J; Caron-Debarle M
    Arterioscler Thromb Vasc Biol; 2013 Apr; 33(4):829-38. PubMed ID: 23393388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms.
    Pandhare J; Cooper SK; Phang JM
    J Biol Chem; 2006 Jan; 281(4):2044-52. PubMed ID: 16303758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
    Lüdtke A; Buettner J; Schmidt HH; Worman HJ
    J Med Genet; 2007 Sep; 44(9):e88. PubMed ID: 17766367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain.
    Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA
    J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered promoter recycling rates contribute to dominant-negative activity of human peroxisome proliferator-activated receptor-gamma mutations associated with diabetes.
    Li G; Leff T
    Mol Endocrinol; 2007 Apr; 21(4):857-64. PubMed ID: 17227883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and bioactivity evaluation of thiazolidinedione derivatives as partial agonists targeting PPARγ.
    Sun J; Liu HY; Zhang YH; Fang ZY; Lv PC
    Bioorg Chem; 2021 Nov; 116():105342. PubMed ID: 34536928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione.
    Chen Z; Vigueira PA; Chambers KT; Hall AM; Mitra MS; Qi N; McDonald WG; Colca JR; Kletzien RF; Finck BN
    J Biol Chem; 2012 Jul; 287(28):23537-48. PubMed ID: 22621923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.
    Gee VM; Wong FS; Ramachandran L; Sethi G; Kumar AP; Yap CW
    J Comput Aided Mol Des; 2014 Nov; 28(11):1143-51. PubMed ID: 25168706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
    Quintanilla RA; Jin YN; Fuenzalida K; Bronfman M; Johnson GVW
    J Biol Chem; 2008 Sep; 283(37):25628-25637. PubMed ID: 18640979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.